Clinical trial
Porphozym in the Treatment of Acute Attacks in AIP
NCT00418795 · Zymenex A/S, Industry · Completed
Key facts
| NCT number | NCT00418795 |
|---|---|
| Title | Porphozym in the Treatment of Acute Attacks in AIP |
| Official title | A Multi-centre, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial, Investigating the Efficacy and Safety of Porphozym (Recombinant Human Porphobilinogen Deaminase) in the Treatment of Acute Attacks in AIP |
| Lead sponsor | Zymenex A/S, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Acute Intermittent Porphyria |
| Intervention type | Drug |
| Interventions | recombinant human porphobilinogen deaminase (Porphozym) |
| Enrollment | 36 |
| Start date | Jun 11, 2003 |
| Primary completion | Jun 20, 2006 |
| Completion | Jun 20, 2006 |
| First posted | Jan 5, 2007 |
| Last update posted | Mar 9, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: